Income Statement

Revenue

+16%

+48%

10Y

Currency: KRW

	Dec-2012	Mar-2013	Jun-2013	Sep-2013	Dec-2013	Mar-2014	Jun-2014	Sep-2014	Dec-2014	Mar-2015	Jun-2015	Sep-2015	Dec-2015	Mar-2016	Jun-2016	Sep-2016	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025
Revenue
Interest Expense	24 392	0	0	10 481	20 653	14 732	19 133	18 464	17 282	16 266	15 798	14 986	14 280	14 345	13 588	13 041	12 115	10 823	10 011	9 151	8 880	8 837	8 958	8 757	8 688	10 979	10 792	10 918	11 279	8 906	9 026	7 705	7 587	6 969	5 916	6 816	7 337	8 150	9 562	10 524	9 387	9 421	10 699	11 402	12 562	12 986	11 448	10 470	10 033	0	0	0
Revenue	397 085 N/A	386 526 -3%	397 591 +3%	401 971 +1%	394 182 -2%	395 535 +0%	386 067 -2%	386 064 0%	412 791 +7%	426 012 +3%	439 803 +3%	447 788 +2%	434 352 -3%	447 416 +3%	452 149 +1%	460 523 +2%	467 465 +2%	471 517 +1%	476 290 +1%	490 656 +3%	502 919 +2%	510 284 +1%	521 667 +2%	534 920 +3%	537 182 +0%	536 809 0%	538 270 +0%	524 767 -3%	511 335 -3%	510 079 0%	512 402 +0%	516 529 +1%	547 336 +6%	560 407 +2%	569 978 +2%	581 827 +2%	606 585 +4%	620 832 +2%	639 806 +3%	660 661 +3%	684 351 +4%	701 393 +2%	895 695 +28%	910 051 +2%	748 527 -18%	929 120 +24%	742 090 -20%	736 543 -1%	719 376 -2%	724 018 +1%	742 847 +3%	764 208 +3%
Gross Profit
Cost of Revenue	(268 107)	(260 365)	(259 320)	(262 588)	(249 699)	(248 007)	(247 800)	(242 821)	(261 518)	(273 619)	(278 296)	(284 806)	(273 729)	(282 184)	(283 866)	(289 650)	(294 121)	(294 200)	(296 504)	(307 709)	(314 286)	(318 378)	(325 530)	(322 058)	(340 142)	(343 676)	(347 316)	(352 714)	(350 216)	(350 751)	(361 290)	(368 302)	(369 810)	(367 206)	(360 118)	(359 582)	(372 209)	(381 077)	(390 548)	(395 943)	(396 397)	(401 974)	(502 110)	(504 189)	(412 984)	(510 549)	(411 745)	(401 807)	(395 878)	(399 371)	(398 659)	(411 754)
Gross Profit	128 978 N/A	126 160 -2%	138 270 +10%	139 383 +1%	144 484 +4%	147 529 +2%	138 268 -6%	143 242 +4%	151 274 +6%	152 391 +1%	161 505 +6%	162 981 +1%	160 623 -1%	165 232 +3%	168 283 +2%	170 873 +2%	173 344 +1%	177 317 +2%	179 786 +1%	182 947 +2%	188 632 +3%	191 905 +2%	196 136 +2%	212 861 +9%	197 040 -7%	193 133 -2%	190 954 -1%	172 053 -10%	161 119 -6%	159 329 -1%	151 113 -5%	148 228 -2%	177 526 +20%	193 202 +9%	209 860 +9%	222 247 +6%	234 376 +5%	239 754 +2%	249 258 +4%	264 719 +6%	287 955 +9%	299 419 +4%	393 585 +31%	405 862 +3%	335 542 -17%	418 571 +25%	330 346 -21%	334 735 +1%	323 498 -3%	324 647 +0%	344 188 +6%	352 455 +2%
Operating Income
Operating Expenses	(119 492)	(117 726)	(117 363)	(115 903)	(118 583)	(119 538)	(121 168)	(127 740)	(133 163)	(136 281)	(138 129)	(139 935)	(138 875)	(141 679)	(144 862)	(148 406)	(148 806)	(152 490)	(156 566)	(158 690)	(166 914)	(172 602)	(176 046)	(176 733)	(175 456)	(176 054)	(175 775)	(175 989)	(180 133)	(182 430)	(180 994)	(180 631)	(178 849)	(185 463)	(194 743)	(199 685)	(203 176)	(205 499)	(207 604)	(219 078)	(224 994)	(229 457)	(292 483)	(297 742)	(235 239)	(292 377)	(232 677)	(236 634)	(241 010)	(247 625)	(253 836)	(256 615)
Selling, General & Administrative	(103 473)	(100 110)	(110 275)	(109 641)	(105 119)	(107 616)	(104 757)	(109 760)	(115 682)	(118 891)	(121 148)	(123 133)	(122 394)	(124 278)	(127 568)	(130 779)	(130 801)	(133 904)	(135 734)	(137 106)	(144 933)	(150 694)	(155 566)	(156 260)	(154 188)	(152 384)	(150 039)	(149 822)	(149 110)	(151 793)	(152 025)	(152 487)	(155 905)	(162 052)	(172 305)	(176 448)	(183 293)	(183 109)	(184 280)	(192 264)	(191 257)	(194 986)	(248 039)	(246 377)	(201 567)	(251 347)	(198 551)	(202 197)	(204 773)	(207 077)	(209 965)	(214 010)
Research & Development	(12 357)	0	0	(5 631)	(13 464)	(11 233)	(15 722)	(16 720)	(17 482)	(17 390)	(16 706)	(16 804)	(16 480)	(17 318)	(17 209)	(17 624)	(18 005)	(18 585)	(20 832)	(21 134)	(21 982)	(21 457)	(20 479)	(20 473)	(21 268)	(21 479)	(24 211)	(24 774)	(25 220)	(24 833)	(23 165)	(22 341)	(22 943)	(22 654)	(21 681)	(22 479)	(19 884)	(21 490)	(22 424)	(25 914)	(33 736)	(34 471)	(44 087)	(43 475)	(33 671)	(40 673)	(34 503)	(34 814)	(36 237)	(39 322)	(42 646)	(41 379)
Depreciation & Amortization	(3 662)	0	0	(631)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(5 804)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	0	(17 616)	(7 088)	0	0	(689)	(689)	(1 260)	0	0	(275)	0	0	(83)	(85)	(3)	0	0	0	(450)	0	(451)	0	0	0	(2 191)	(1 525)	(1 393)	0	(5 804)	(5 804)	(5 803)	0	(757)	(758)	(758)	0	(900)	(900)	(900)	0	0	(357)	(7 890)	0	(357)	377	377	0	(1 226)	(1 226)	(1 226)
Operating Income	9 486 N/A	8 434 -11%	20 907 +148%	23 480 +12%	25 900 +10%	27 991 +8%	17 100 -39%	15 503 -9%	18 110 +17%	16 111 -11%	23 377 +45%	23 047 -1%	21 749 -6%	23 554 +8%	23 422 -1%	22 467 -4%	24 538 +9%	24 827 +1%	23 220 -6%	24 257 +4%	21 718 -10%	19 304 -11%	20 091 +4%	36 129 +80%	21 584 -40%	17 079 -21%	15 179 -11%	(3 936) N/A	(19 014) -383%	(23 101) -21%	(29 881) -29%	(32 403) -8%	(1 323) +96%	7 737 N/A	15 115 +95%	22 560 +49%	31 200 +38%	34 256 +10%	41 654 +22%	45 641 +10%	62 961 +38%	69 962 +11%	101 102 +45%	108 120 +7%	100 304 -7%	126 194 +26%	97 669 -23%	98 101 +0%	82 488 -16%	77 022 -7%	90 352 +17%	95 840 +6%
Pre-Tax Income
Interest Income Expense	(22 074)	(20 504)	(21 049)	(19 689)	(16 253)	(18 366)	(15 141)	(14 666)	(9 421)	(9 179)	(8 808)	(9 145)	(13 988)	(15 329)	(15 577)	(14 875)	(14 350)	(13 772)	(11 572)	(10 603)	(13 044)	(10 339)	(10 269)	(11 600)	(7 760)	(7 693)	(7 316)	(5 037)	(11 341)	(9 876)	(10 195)	(10 378)	(10 332)	(9 690)	(10 264)	(9 204)	(8 356)	(8 321)	(8 336)	(7 482)	(2 748)	(761)	(1 543)	(3 182)	(3 979)	(4 766)	(2 828)	(2 155)	(2 365)	(1 936)	(404)	278
Non-Reccuring Items	0	0	0	0	(1 025)	(1 259)	(1 259)	0	(1 406)	(276)	0	(359)	(197)	0	0	(160)	(160)	(160)	(610)	0	(450)	0	(665)	(798)	(2 191)	0	0	0	817	0	0	0	(760)	0	0	0	(900)	0	0	0	(7 533)	(7 890)	(7 533)	0	0	734	0	0	(849)	0	0	0
Gain/Loss on Disposition of Assets	(2 575)	0	0	(2 637)	(5 865)	(4 545)	(5 929)	(5 658)	(5 354)	(4 974)	(5 344)	(4 446)	(4 339)	(4 433)	(3 943)	(4 388)	(4 458)	(4 417)	(4 229)	(4 214)	(3 952)	(3 692)	(3 927)	(4 038)	(4 104)	(7 032)	(6 411)	(5 989)	(2 926)	(2 620)	(2 447)	(2 304)	(1 971)	(2 790)	(2 323)	(1 708)	(1 048)	72	125	43	3	2	(1 064)	(1 088)	(1 088)	(1 091)	(24)	(22)	465	463	0	0
Total Other Income	11	(2 603)	(1 765)	(5)	649	975	1 189	780	(68)	(741)	(1 502)	(897)	(944)	(1 082)	(2 140)	(8 209)	1 511	(401)	(711)	10 049	(5 620)	(1 774)	8 336	(7 017)	2 705	(1 355)	(9 346)	1 548	(1 871)	2 317	2 100	1 803	1 181	(248)	(451)	(986)	(364)	(168)	(399)	(657)	(7 321)	(5 855)	(2 860)	(37 147)	(40 401)	(39 796)	(42 123)	(6 729)	2 681	3 292	(1 237)	(6 132)
Pre-Tax Income	(15 152) N/A	(14 673) +3%	(1 907) +87%	1 149 N/A	3 406 +196%	4 794 +41%	(4 042) N/A	(4 043) 0%	1 861 N/A	941 -49%	7 724 +721%	8 202 +6%	2 281 -72%	2 711 +19%	1 762 -35%	(5 165) N/A	7 081 N/A	6 076 -14%	6 097 +0%	19 489 +220%	(1 348) N/A	3 499 N/A	13 565 +288%	12 674 -7%	10 234 -19%	998 -90%	(7 895) N/A	(13 415) -70%	(34 335) -156%	(33 281) +3%	(40 423) -21%	(43 282) -7%	(13 205) +69%	(4 990) +62%	2 077 N/A	10 662 +413%	20 533 +93%	25 839 +26%	33 044 +28%	37 545 +14%	45 362 +21%	55 459 +22%	88 101 +59%	66 703 -24%	54 836 -18%	81 274 +48%	52 695 -35%	89 195 +69%	82 420 -8%	78 842 -4%	88 711 +13%	89 987 +1%
Net Income
Tax Provision	(5 242)	(4 890)	(7 218)	(7 723)	(1 131)	(1 698)	1 394	1 392	(414)	(515)	(2 856)	(2 823)	(145)	365	(14 538)	(13 457)	(18 015)	(17 549)	(2 402)	(5 267)	606	(512)	(1 001)	(3 563)	(2 177)	(2 230)	(374)	3 984	9 060	9 938	7 101	11 773	(2 070)	(3 468)	(5 824)	(12 341)	(21 974)	(21 911)	(24 473)	(25 858)	(15 509)	(19 646)	(21 763)	(26 416)	(16 406)	(22 757)	(17 042)	(15 785)	(17 379)	(16 419)	(36 664)	(27 199)
Income from Continuing Operations	(20 394)	(19 562)	(9 125)	(6 575)	2 275	3 095	(2 648)	(2 651)	1 447	426	4 868	5 379	2 136	3 076	(12 776)	(18 621)	(10 934)	(11 471)	3 698	14 224	(742)	2 989	12 566	9 113	8 057	(1 231)	(8 269)	(9 431)	(25 275)	(23 342)	(33 321)	(31 508)	(15 275)	(8 458)	(3 746)	(1 679)	(1 441)	3 928	8 571	11 687	29 853	35 812	66 337	40 287	38 430	58 518	35 653	73 410	65 040	62 423	52 047	62 788
Income to Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	5	34	(11)	418	480	474	656	359	443	2 039	2 021	466	316	(1 424)	(1 424)	0	0	0	0	0	0
Net Income (Common)	(20 422) N/A	(19 587) +4%	(9 151) +53%	(6 593) +28%	2 245 N/A	2 870 +28%	(3 064) N/A	(3 272) -7%	617 N/A	(195) N/A	4 447 N/A	5 159 +16%	2 117 -59%	3 056 +44%	(12 795) N/A	(18 636) -46%	(11 636) +38%	(12 344) -6%	2 650 N/A	12 560 +374%	(2 058) N/A	1 309 N/A	10 231 +682%	7 052 -31%	6 795 -4%	(1 957) N/A	(8 163) -317%	(8 981) -10%	(24 785) -176%	(22 708) +8%	(32 241) -42%	(30 582) +5%	(14 381) +53%	(7 989) +44%	(3 099) +61%	(1 110) +64%	(916) +17%	4 263 N/A	8 157 +91%	11 035 +35%	30 312 +175%	35 760 +18%	63 415 +77%	38 775 -39%	35 096 -9%	53 869 +53%	33 440 -38%	68 958 +106%	60 781 -12%	58 572 -4%	48 851 -17%	59 293 +21%
EPS (Diluted)	-1 361.46 N/A	-1 224.18 +10%	-538.29 +56%	-387.82 +28%	132.05 N/A	151.05 +14%	-170.22 N/A	-181.77 -7%	34.27 N/A	-9.75 N/A	211.76 N/A	245.66 +16%	100.8 -59%	145.52 +44%	-609.28 N/A	-887.42 -46%	-554.09 +38%	-587.8 -6%	126.19 N/A	598.09 +374%	-98 N/A	62.33 N/A	487.19 +682%	335.8 -31%	323.57 -4%	-93.19 N/A	-371.04 -298%	-427.66 -15%	-1 180.23 -176%	-1 081.33 +8%	-1 535.28 -42%	-1 456.28 +5%	-684.8 +53%	-380.42 +44%	-140.28 +63%	-50.24 +64%	-38.33 +24%	193.07 N/A	358.68 +86%	485.26 +35%	1 267.1 +161%	1 531.79 +21%	2 718.38 +77%	1 662.56 -39%	1 503.91 -10%	2 309.46 +54%	1 433.67 -38%	2 956.47 +106%	2 605.86 -12%	2 524.09 -3%	2 122.6 -16%	2 590.7 +22%

Income Statement Balance Sheet Cash Flow Statement

JW Pharmaceutical Corp
KRX:001060

Income Statement

Earnings Waterfall
JW Pharmaceutical Corp

Income Statement
JW Pharmaceutical Corp

See Also

Company

Help

Tools

Stocks

JW Pharmaceutical Corp KRX:001060

Income Statement

Earnings Waterfall JW Pharmaceutical Corp

Income Statement JW Pharmaceutical Corp

See Also

Company

Help

Tools

Stocks

JW Pharmaceutical Corp
KRX:001060

Earnings Waterfall
JW Pharmaceutical Corp

Income Statement
JW Pharmaceutical Corp